The stimulation of GLP-1 secretion and delivery of GLP-1 agonists via nanostructured lipid carriers. Issue 2 (13th December 2017)

• Record Type: Journal Article
• Authors: Shrestha, Neha; Bouttefeux, Oriane; Vanvarenberg, Kevin; Lundquist, Patrik; Cunarro, Juan; Tovar, Sulay; Khodus, Georgiy; Andersson, Ellen; Keita, Åsa V.; Gonzalez Dieguez, Carlos; Artursson, Per; Préat, Véronique; Beloqui, Ana
• Is Part Of: Nanoscale. Volume 10:Issue 2(2018)
• Page Start: 603
• Page End: 613
• Publication Date: 2017-12-13
• Subjects: Nanoscience -- Periodicals; Nanotechnology -- Periodicals; 620.505
• DOI: 10.1039/c7nr07736j
• Languages: English
• ISSNs: 2040-3364

Abstract

Abstract : Dual-action nanostructured lipid carriers act as an oral carrier of the GLP-1 agonist and also stimulate endogenous GLP-1 secretion. Abstract : Nanoparticulate based drug delivery systems have been extensively studied to efficiently encapsulate and deliver peptides orally. However, most of the existing data mainly focus on the nanoparticles as a drug carrier, but the ability of nanoparticles having a biological effect has not been exploited. Herein, we hypothesize that nanostructured lipid carriers (NLCs) could activate the endogenous glucagon-like peptide-1 (GLP-1) secretion and also act as oral delivery systems for GLP-1 analogs (exenatide and liraglutide). NLCs effectively encapsulated the peptides, the majority of which were only released under the intestinal conditions. NLCs, with and without peptide encapsulation, showed effective induction of GLP-1 secretion in vitro from the enteroendocrinal L-cells (GLUTag). NLCs also showed a 2.9-fold increase in the permeability of exenatide across the intestinal cell monolayer. The intestinal administration of the exenatide and liraglutide loaded NLCs did not demonstrate any glucose lowering effect on normal mice. Further, ex vivo studies depicted that the NLCs mainly adhered to the mucus layer. In conclusion, this study demonstrates that NLCs need further optimization to overcome the mucosal barrier in the intestine; nonetheless, this study also presents a promising strategy to use a dual-action drug delivery nanosystem which synergizes its own biological effect and that of the encapsulated drug molecule.